KYORIN Holdings, Inc. - Your health is Kyorin’s mission.

Long-Term Vision - Our Vision HOPE100

Top Message - Mobilizing its comprehensive strength, the Kyorin Group aims to achieve its long-term vision HOPE100.

Medium-Term Business Plan HOPE 100 -Stage3- FY2020-FY2023

Annual Report 2019

News・Topics

March 6, 2023

KYORIN and Sumitomo Pharma Enter into License Agreement of Vibegron in Taiwan and Other Asian Countries
February 6, 2023

Summary of Consolidated Financial Results(For the third quarter ended December 31, 2022) [Japanese GAAP]
February 6, 2023

Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Feb 6, 2023) - Supplementary Information
November 9, 2022

KYORIN and SUSMED conclude Collaboration Research and Sales Agreement for development of DTx in Otolaryngology Field
November 9, 2022

Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Nov 9, 2022) - Supplementary Information

Group Pickup

About Kyorin Group

Group Business

Investor information

CSR

Company Information

Recruit

Kyorin Group

KYORIN Pharmaceutical Co., Ltd.

Ethical drugs, over-the-counter drugs and others

KYORIN Rimedio Co., Ltd.

Generic drugs, over-the-counter drugs and others

KYORIN Pharmaceutical Facilities Co.,Ltd.

Manufacture and sales of prescription drugs